文献速递膀胱癌与上尿路尿路上皮癌

诱导后尿肿瘤DNA可预测非肌层浸润性膀胱癌维持膀胱灌注治疗的疗效

Postinduction Urine Tumor DNA Is Predictive for Response to Maintenance Intravesical Therapy in Non-muscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2026-10-31

INSITE 前瞻性多中心观察研究评估诱导后尿肿瘤DNA(utDNA)对维持膀胱灌注治疗(IVT)获益的预测价值,共分析140例可评估患者,47%接受维持治疗。utDNA阴性者维持治疗无显著无复发生存(RFS)获益(HR 1.35,95%CI 0.50-3.64,p=0.6),24个月RFS均为88%;utDNA阳性者接受维持治疗有生存优势(HR 0.22,95%CI 0.09-0.52,p<0.001),24个月RFS为68%对16%。

要点

  • 诱导后utDNA阴性者维持IVT无显著RFS获益,24个月RFS均为88%。
  • 诱导后utDNA阳性者接受维持IVT的RFS显著优于未接受者(HR 0.22)。
  • 传统临床病理危险因素与复发无显著关联。

核心结论

  • 诱导后utDNA可识别从维持IVT获益的患者与可考虑降阶梯治疗的患者,支持在指南范围内实现个体化治疗。

研究设计与样本

  • INSITE为前瞻性设计的多中心观察性研究,共140例可评估患者,其中47%接受维持IVT。
  • utDNA状态采用既往验证的算法判定,主要结局为无复发生存(RFS)。

主要发现

  • utDNA阴性患者接受维持治疗无显著RFS获益(HR 1.35,95%CI 0.50-3.64,p=0.6),24个月RFS为88%且与是否维持无关。
  • utDNA阳性患者接受维持治疗较未接受者RFS显著更优(HR 0.22,95%CI 0.09-0.52,p<0.001),24个月RFS分别为68%与16%。
  • 传统临床病理危险因素与复发无显著关联。

关键数值与推荐

  • utDNA阴性:维持治疗HR 1.35(95%CI 0.50-3.64,p=0.6),24个月RFS 88%。
  • utDNA阳性:维持治疗HR 0.22(95%CI 0.09-0.52,p<0.001),24个月RFS 68% vs 16%。

临床怎么用

  • 对诱导后utDNA阴性患者,可考虑在指南范围内讨论减少维持IVT强度。
  • 对诱导后utDNA阳性患者,应强化维持IVT以改善RFS。
  • utDNA检测有助于在指南框架内实现个体化膀胱灌注治疗决策。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-muscle-invasive bladder cancer has a high recurrence risk and is typically managed with transurethral resection of bladder tumors followed by intravesical therapy (IVT) induction. Thereafter, guidelines support maintenance IVT, but real-world adherence is reported as low as 2%. Management is complicated by ambiguity regarding which patients derive the greatest benefit, highlighting the need for biomarkers to inform management decisions. Postinduction urine tumor DNA (utDNA) was evaluated as a predictor of maintenance benefit in INSITE, a prospectively designed multicenter observational study. utDNA status was determined using a previously validated algorithm. The primary outcome was recurrence-free survival (RFS). Among 140 evaluable patients, 47% received maintenance IVT. For patients with utDNA-negative status, maintenance therapy provided no significant RFS benefit (hazard ratio [HR] 1.35, 95% confidence interval [CI] = 0.50-3.64, p = 0.6), and RFS was 88% at 24 mo regardless of whether patients received maintenance. Conversely, patients with utDNA-positive status who received maintenance experienced a survival advantage over those who did not (HR 0.22, 95% CI = 0.09-0.52, p < 0.001). RFS was 68% in patients with utDNA-positive status who received maintenance but was just 16% in those who remained untreated at 24 mo. Traditional clinicopathologic risk factors were not significantly associated with recurrence. Postinduction utDNA identifies patients who benefit from maintenance therapy versus those who may consider de-escalation, enabling personalized care within guideline ranges.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Lotan Y, Korman H, Gadzinski A, et al. Postinduction Urine Tumor DNA Is Predictive for Response to Maintenance Intravesical Therapy in Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2026. PMID: 42966692. doi:10.1016/j.euo.2026.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。